2021
DOI: 10.1158/2643-3230.bcd-20-0108
|View full text |Cite
|
Sign up to set email alerts
|

Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma

Abstract: Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC targeted genes in multiple myeloma (MM) cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases histone H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. Using genetic ablation together wit… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
47
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 21 publications
(48 citation statements)
references
References 68 publications
(89 reference statements)
1
47
0
Order By: Relevance
“…In contrast to acquired drug resistance, de novo drug resistance occurs quickly and is reversible, suggesting that epigenetic mechanisms assume a critical role in regulating the transcription program underlying the resistance [ 3 ]. Recent literature has documented several chromatin regulators in drug resistance and myelomagenesis [ 9 , 10 , 11 , 12 , 13 , 14 , 15 ], including in the context of the BM microenvironment [ 5 , 16 ]. However, few have investigated the contribution of chromatin reorganization to the BMSC-induced transcription changes in MM cells and the associated regulatory mechanisms linked to de novo drug resistance.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast to acquired drug resistance, de novo drug resistance occurs quickly and is reversible, suggesting that epigenetic mechanisms assume a critical role in regulating the transcription program underlying the resistance [ 3 ]. Recent literature has documented several chromatin regulators in drug resistance and myelomagenesis [ 9 , 10 , 11 , 12 , 13 , 14 , 15 ], including in the context of the BM microenvironment [ 5 , 16 ]. However, few have investigated the contribution of chromatin reorganization to the BMSC-induced transcription changes in MM cells and the associated regulatory mechanisms linked to de novo drug resistance.…”
Section: Introductionmentioning
confidence: 99%
“…Similar to the function of Lid in the developmental genes in Drosophila cells, we recently showed that KDM5A positively regulates its target genes via H3K4me3 demethylation in mammalian cells [35]. KDM5A coexists with MYC and the components of the transcriptional machinery, including CDK7, CDK9, and RNAPII, across the genome of multiple myeloma cells [35]. Importantly, KDM5A depletion and a selective catalytic inhibitor of KDM5 were found to reduce the expression of MYC target genes, concomitant with increased H3K4me3 and reduced Ser2/Ser5-phosphorylated RNAPII at the MYC target gene loci [35].…”
Section: Demethylase-dependent Transcriptional Activationmentioning
confidence: 59%
“…Based on these findings, researchers proposed that H3K4me3 demethylation by Lid is required for resetting the chromatin state and starting a new transcription cycle, the disruption of which leads to transcription failure [56]. Similar to the function of Lid in the developmental genes in Drosophila cells, we recently showed that KDM5A positively regulates its target genes via H3K4me3 demethylation in mammalian cells [35]. KDM5A coexists with MYC and the components of the transcriptional machinery, including CDK7, CDK9, and RNAPII, across the genome of multiple myeloma cells [35].…”
Section: Demethylase-dependent Transcriptional Activationmentioning
confidence: 82%
See 2 more Smart Citations